INS and Hypoglycemia: 1st generation non-selective betablockers block both β1 and β2 receptors, thus decreasing insulin secretion, glycolysis and lipolysis, while increasing glycogenolysis and gluconeogenesis and are prone to mask the symptoms of hypoglycemia (148, 149).